Abstract
BACKGROUND: Individuals with CKD are at a higher risk of cardiovascular morbidity and mortality. Acidosis is positively correlated with CKD progression and elevated systolic BP. Sodium bicarbonate is an efficacious treatment of acidosis, although this may also increase systolic BP. In this systematic review and meta-analysis, we summarize the evidence evaluating systolic BP and antihypertensive medication change (which may indicate systolic BP change) in response to sodium bicarbonate therapy in individuals with CKD. METHODS: Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) trials registry databases were searched for randomized control trials where sodium bicarbonate was compared with placebo/usual care in CKD stage G1-5 non-dialysis-dependent populations. Random effects meta-analyses were used to evaluate changes in systolic BP and BP-modifying drugs after sodium bicarbonate intervention. RESULTS: Fourteen randomized control trials (2110 individuals, median follow-up 27 [interquartile range 97] weeks, mean age 60 [SD 10] years, mean systolic BP 136 [SD 17] mm Hg, mean eGFR 38 [SD 10] ml/min, mean serum bicarbonate 22 [SD 4] mmol/L) were eligible for inclusion. Meta-analysis suggested that sodium bicarbonate did not influence systolic BP in individuals with CKD stage G1-5. Results were consistent when stratifying by dose of sodium bicarbonate or duration of intervention. Similarly, there was no significant increase in the use of antihypertensive medication or diuretics in individuals taking sodium bicarbonate, whereas there was a greater decrease in antihypertensive medication use in individuals taking sodium bicarbonate compared with controls. CONCLUSIONS: Our results suggest, with moderate certainty, that sodium bicarbonate supplementation does not adversely affect systolic BP in CKD or negatively influence antihypertensive medication requirements.
| Original language | English |
|---|---|
| Pages (from-to) | 435-445 |
| Number of pages | 11 |
| Journal | Clinical journal of the American Society of Nephrology : CJASN |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2023 |
Bibliographical note
Funding Information:B. Beynon-Cobb was funded by a CRN West Midlands Personal Development Award and the Center for Care Excellence at UHCW NHS Trust. P. Louca was supported by the Chronic Disease Research Foundation (CDRF–15/2018). C. Menni was funded by the Chronic Disease Research Foundation (CDRF) and by the MRC Aim-Hy project grant. S. Padmanabhan was funded by the British Heart Foundation (BHF CS/16/1/31878; RE/18/ 6/34217). Stanningley Pharma supported open access publication of this manuscript.
Publisher Copyright:
© 2023 The Authors. Published by Wolters Kluwer Health, Inc.